Pharmacokinetics and Bioequivalence of 2 Tablet Formulations of Olanzapine in Healthy Chinese Volunteers: a Randomized, Open-Label, Single-Dose Study

Abstract

Background:

Olanzapine is a widely used agent for the treatment of schizophrenia.

Objective:

The aim of this study was to evaluate bioequivalence of two 10-mg tablet formulations of olanzapine following single oral dose in adult male volunteers.

Methods:

This was a randomized, single-dose, open-label, crossover bioequivalence study. Plasma samples were collected before dosing and at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0, 24.0, 36.0, 48.0, 72.0, 96.0, 120.0 and 144.0 h after dosing. Plasma concentrations of olanzapine were determined by using a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Statistical analysis of the pharmacokinetic parameters C_max, AUC_0–144, and AUC_0–∞ was conducted to determine bioequivalence. Adverse events were monitored, recorded and evaluated by investigators throughout the study.

Results:

24 healthy male Chinese volunteers between the ages of 18–40 years with a body mass index (BMI) between 19 and 24 kg/m² were enrolled in the study. The mean (SD) C_max, AUC_0–144, and AUC_0–∞ values after administration of the test and reference formulations, respectively, were as follows: 18.91 (5.320) vs. 18.44 (4.758) ng/mL, 582.9 (118.23) vs. 587.3 (127.12) ng/mL · h, and 615.4 (131.39) vs. 615.8 (137.45) ng/mL · h. The 90% CIs for the ratios of AUC_0–144 and C_max were 96.9% to 102.4% and 93.7% to 110.2%, respectively. The relative bioavailability of the test formulation to reference formulation was 100.1%. Both formulations were generally well tolerated and no serious AEs were reported in the study.

Conclusions:

The 90% CIs for the ratios of mean C_max, AUC_0–144, and AUC_0–∞ met the regulatory criteria for bioequivalence.

Key words

olanzapine - bioequivalence - pharmacokinetics - LC-MS/MS - adverse events

• References

• 1 FDA. Electronic Orange Book. April 2007
• 2 Beasley Jr CM, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-123
• 3 McCormack PL, Wiseman LR. Olanzapine: A review of its use in the management of bipolar I disorder. Drugs 2004; 64: 2709-2726
• 4 Lieberman JA, Tollefson G, Tohen M et al. HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160 (08) 1396-1404
• 5 Eishafeey AH, Eisherbiny MA, Fathallah MM. A Single-Dose Randomized, Two-Way Crossover Study Comparing Two Olanzapine Tablet Products in Healthy Adult Male Volunteers Under Fasting Conditions. Clinical Therapeutics 2009; 31 (03) 600-608
• 6 Mitchell M, Riesenberg R, Bari MA et al. A Double-Blind, Randomized Trial to Evaluate the Pharmacokinetics and Tolerability of 30 or 40 mg/d Oral Olanzapine Relative to 20 mg/d Oral Olanzapine in Stable Psychiatric Subjects. Clinical Therapeutics 2006; 28 (06) 881-892
• 7 Zoccali R, Muscatello MR, Torre DL et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res 2003; 48 (04) 411-414
• 8 Callaghan JT, Bergstrom RF, Ptak LR et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177-193
• 9 Wu TH, Chiu CC, Shen WW et al. Phamacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (08) 1889-1893
• 10 World Medical Association Declaration of Helsinki (WMA). Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18^th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52^nd WMA General Assembly, Edinburgh, Scotland, October 7, 2000 http://www.wma.net/e/policy/b3.htm Accessed September 20, 2007
• 11 European Agency for the Evaluation of Medicinal Products (EMEA), International Conference on Harmonisation–World Health Organization . Guideline for Good Clinical Practice. ICH topic E 6 (R1). Geneva, Switzerland: WHO; 2002. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed September 26, 2007
• 12 State Food and Drug Administration of China. Guideline for Good Clinical Principles. http://www.sda.gov.cn/WS01/CL0053/24473.html Accessed August 6, 2003
• 13 Zhang MQ, Jia JY, Lu C et al. Development and validation of a liquid chromatography-isotope dilution tandem mass spectrometry for determination of olanzapine in human plasma and its application to bioavailability study. Acta Pharmaceutica Sinica 2010; 45 (06) 767-771
• 14 Chin C, Zhang ZP, Karnes HT. A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine. Journal of Pharmaceutical and Biomedical Analysis 2004; 35 (05) 1149-1167
• 15 Berna M, Ackermann B, Ruterbories K et al. Determination of olanzapine in human blood by liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 767 (01) 163-168
• 16 Center for Drug Evaluation, State Food and Drug Administration of China. Guidance for bioavailability and bioequvlence studies of chemical drug. http://www.cde.org.cn/zdyz.do?method=largePage&id=2066 Accessed March, 2005
• 17 Shumaker RC. PKCALC: A BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 1986; 17 (3–4) 331-348
• 18 Choi S, DiSilvio B, Unangst J et al. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sciences 2007; 81 (12) 1024-1030